Open Access
Article
c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy
Kazuyuki Matsushita1,Takeshi Tomonaga1,Toshiko Kajiwara1,Hideaki Shimada1,Sakae Itoga1,Takaki Hiwasa1,Shuji Kubo1,Takenori Ochiai1,Hisahiro Matsubara1,Fumio Nomura1
1
Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670. kmatsu@faculty.chiba-u.jp
DOI: 10.2741/3461 Volume 14 Issue 9, pp.3401-3408
Published: 01 January 2009
(This article belongs to the Special Issue Current gene therapy for cancer)
Abstract

Based on the genetic background of cancer, we have been trying to develop novel diagnostic and therapeutic strategies against human cancers. c-myc gene activation has been detected in many human cancers, indicating a key role of c-myc in tumor development. Thus targeting c-myc gene suppression is a promising strategy for cancer treatment. Recently, an interaction between FIR (FUSE-Binding Protein-Interacting Repressor) and TFIIH/p89/XPB helicase was found to repress c-myc transcription and so might be important for suppressing tumor formation. Previously, we have shown that the expression of splicing variant of FIR is elevated in colorectal cancer tissues and promotes tumor development by disabling FIR-repression to sustain high levels of c-Myc, opposing apoptosis in cancer cells. In this study, FIR recombinant adenovirus vector induces tumor growth suppression against tumor xenografts in animal model experiment. Together, one clue to the development of cancer diagnosis and therapies directed against c-Myc may go through FIR and its splicing variant.

Share and Cite
Kazuyuki Matsushita, Takeshi Tomonaga, Toshiko Kajiwara, Hideaki Shimada, Sakae Itoga, Takaki Hiwasa, Shuji Kubo, Takenori Ochiai, Hisahiro Matsubara, Fumio Nomura. c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Frontiers in Bioscience-Landmark. 2009. 14(9); 3401-3408.